Saturday, November 2, 2019

12:30 -14:00 Trianti Hall

PARP Inhibitors for Newly Diagnosed Advanced Ovarian Cancer: Is it Time for a New Treatment Paradigm?

 

12:30  Welcome and Introductions
Andreas du Bois, Germany

12:35  Exploring the Rationale for Earlier Intervention with PARP Inhibitors
Charles Gourley, United Kingdom

12:55 PARP Inhibitors in the First-line Setting: A Review of the Evidence
Sandro Pignata, Italy
Isabelle Ray-Coquard, France

13:35 Interpretation, Panel Discussion and Audience Q&A
Andreas du Bois, Germany

 

 

12:30 The Pelvic exenteration in the aortic node positive patients
Gwenael Ferron, France

12:45 Surgery or Radiotherapy in the treatment of Pelvic sidewall relapse
Vito Chiantera, Italy

13:00 Reconstruction after Pelvic Exenteration: Just Standard or More Complex Reconstruction?
Luis M. Chiva, Spain

13:10 Reconstruction after Pelvic Exenteration: Just Standard or More Complex Reconstruction?
Jalid Sehouli, Germany

13:20 Debate

13:30 Ovarian cancer relapse after PARP therapy, Surgery or Chemotherapy
Anna Fagotti, Italy

13:40 Ovarian cancer relapse after PARP therapy, Surgery or Chemotherapy
Barbara Schmalfeldt, Germany

13:50 Debate

 

Chair: Frédéric Kridelka, Belgium

15:30 Introduction by Chairman
Frédéric Kridelka, Belgium

15:35 LACC Trial – Interpreting of the Trial Results and Implications on Future Clinical Trial Design
Andreas Obermair, Austria

15:50 Developments in ICG Technology in Targeting Sentinel Node Biopsy
Karl Tamussino, Austria

16:05 Is the Future of Surgery in Genycological Cancer Bright or Gloomy?
Frédéric Kridelka, Belgium

16:20 Questions and Answers
All faculty

 

15:30 Introduction
Andreas du Bois, Germany

15:35 Latest data on PARPi maintenance in first-line ovarian cancer Antonio
González-Martin, Spain

15:50 How to treat newly diagnosed ovarian cancer patients: considering all the options
Andreas du Bois, Germany

16:05 Efficacy of anti-PD-1 in endometrial cancer: what's the news?
Ana Oaknin, Spain

16:20 Conclusion
Nicoletta Colombo, Italy

 

Sunday, November 3, 2019

13:00-14:30 Trianti Hall

Evolving treatments for recurrent/metastatic cervical cancer: looking beyond the current standard of care

CHAIR: Mansoor Raza Mirza, Denmark

 

The symposium session will be primarily discussion based, focusing on the opinions and insights of the expert panel as well as audience input and feedback. Some slides will be used to set the scene and guide the discussions, but the symposium does not fit into the standard presentation/discussion format.

Introduction
Mansoor Mirza, Denmark

Current Treatment Landscape for Recurrent/Metastatic Cervical Cancer
Mansoor Mirza, Denmark

Surgical Intervention in Recurrent Cervical Cancer
David Cibula, Czech Republic

Patient Perspectives on Treatment
David Cibula, Czech Republic

New Treatments in Development for Recurrent/Metastatic Cervical Cancer: Immuno-Oncology
Mansoor Mirza, Denmark

New Treatments in Development for Recurrent/Metastatic Cervical Cancer: Antibody Drug Conjugates
Ana Oaknin, Spain

Panel Q&A

 

13:00-14:30 Banqueting Hall

The Past, Present and Future of PARP Inhibitors in Recurrent Ovarian Cancer

CHAIR: Domenica Lorusso, Italy

 

13:00 Welcome and Introduction
Domenica Lorusso, Italy

13:05  All Eyes on PARPi: Advances in Maintenance Therapy for Recurrent Ovarian Cancer
Andreas du Bois, Germany

13:25 Case Studies: Informed Decision Making for the Treatment of Patients with Recurrent Ovarian Cancer
Domenica Lorusso, Italy

13:45 Is Active Surveillance Active Enough for Patients with Recurrent Ovarian Cancer?
Panel

14:05 Looking to the Future of PARP Inhibitors in Ovarian Cancer Treatment
Eric Pujade-Lauraine, France

14:20 Panel Q&A and Close
Domenica Lorusso, Italy

 

 

16:00 The place of da Vinci robotic-assisted surgery in an Enhanced Recovery Program
Eric Lambaudie, France

16:30 Early recovery after da Vinci robotic-assistedb post operative results
Celine Lönnefors, Sweden

 

 

16.00 Introduction: What has changed?
Sandro Pignata, Italy

16.15 When platinum re-challenge might be justified
Domenica Lorusso, Italy

16.30 What if the symptomatic response is a priority?
Antonio González, Spain

16.45 Facing an early symptomatic relapse
Isabelle Ray-Coquard, France